Treatment of tauopathies

Lars Ittner; Arne Ittner

Treatment of tauopathies

Lars Ittner (Inventor), Arne Ittner (Inventor)

Research output: Patent

Abstract

Methods of treating a tauopathy in a subject by either administering full length isoform 2 of ρ38γ or its constitutively active mutant ρ38γ D179A. This promotes phosphorylation at threonine in the sequence SSPGSPGTPGSRSR of tau, equivalent to amino acid position threonine 205 (T205) of human tau. The methods also include introducing a phosphomimetic of a phosphorylated tau, wherein the phosphorylated tau has been phosphorylated at threonine in the sequence SSPGSPGTPGSRSR of the tau. The method of treatment results in improving the cognitive ability in a subject suffering from cognitive impairment associated with a tauopathy and reducing tau aggregates and neurofibrillary tangles.

Original language	English
Patent number	EP4034240
IPC	C12N 15/ 11 A I,A61P 25/28,A01K 67/027,A61K 31/7105,A61K 38/45,A61K 48/00
Priority date	23/09/19
Publication status	Published - 3 Aug 2022

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=EP370532481

4 Patent

Treatment of tauopathies
Ittner, L. & Ittner, A., 27 Oct 2022, IPC No. C07K 14/ 47 A I, A61K 31/713, A61K 39/395, A61K 47/64, A61K 9/28, A61P 25/28, Patent No. US2022339183, Priority date 23 Sept 2019, Priority No. AU2019903530
Research output: Patent

Open Access
Treatment of tauopathies
Ittner, L. & Ittner, A., 10 Mar 2022, IPC No. C12N 15/ 11 A I, A61P 25/28, A61K 31/7105, A61K 38/45, Patent No. AU2020353719, 23 Sept 2020, Priority date 23 Sept 2019, Priority No. AU2019903530
Research output: Patent

Open Access
Treatment of tauopathies
Ittner, L. & Ittner, A., 1 Apr 2021, IPC No. C12N 15/ 11 A I, A61P 25/28 2006.1, A61K 38/45 2006.1, A61K 31/7105 2006.1, Patent No. WO2021056064, 23 Sept 2020, Priority date 23 Sept 2019, Priority No. AU20190903530
Research output: Patent

Open Access

Cite this

@misc{2f6c42e7c84b47cfac14bb60c49959bc,

title = "Treatment of tauopathies",

abstract = "Methods of treating a tauopathy in a subject by either administering full length isoform 2 of ρ38γ or its constitutively active mutant ρ38γ D179A. This promotes phosphorylation at threonine in the sequence SSPGSPGTPGSRSR of tau, equivalent to amino acid position threonine 205 (T205) of human tau. The methods also include introducing a phosphomimetic of a phosphorylated tau, wherein the phosphorylated tau has been phosphorylated at threonine in the sequence SSPGSPGTPGSRSR of the tau. The method of treatment results in improving the cognitive ability in a subject suffering from cognitive impairment associated with a tauopathy and reducing tau aggregates and neurofibrillary tangles.",

author = "Lars Ittner and Arne Ittner",

year = "2022",

month = aug,

day = "3",

language = "English",

type = "Patent",

note = "EP4034240; C12N 15/ 11 A I,A61P 25/28,A01K 67/027,A61K 31/7105,A61K 38/45,A61K 48/00",

}

TY - PAT

T1 - Treatment of tauopathies

AU - Ittner, Lars

AU - Ittner, Arne

PY - 2022/8/3

Y1 - 2022/8/3

N2 - Methods of treating a tauopathy in a subject by either administering full length isoform 2 of ρ38γ or its constitutively active mutant ρ38γ D179A. This promotes phosphorylation at threonine in the sequence SSPGSPGTPGSRSR of tau, equivalent to amino acid position threonine 205 (T205) of human tau. The methods also include introducing a phosphomimetic of a phosphorylated tau, wherein the phosphorylated tau has been phosphorylated at threonine in the sequence SSPGSPGTPGSRSR of the tau. The method of treatment results in improving the cognitive ability in a subject suffering from cognitive impairment associated with a tauopathy and reducing tau aggregates and neurofibrillary tangles.

AB - Methods of treating a tauopathy in a subject by either administering full length isoform 2 of ρ38γ or its constitutively active mutant ρ38γ D179A. This promotes phosphorylation at threonine in the sequence SSPGSPGTPGSRSR of tau, equivalent to amino acid position threonine 205 (T205) of human tau. The methods also include introducing a phosphomimetic of a phosphorylated tau, wherein the phosphorylated tau has been phosphorylated at threonine in the sequence SSPGSPGTPGSRSR of the tau. The method of treatment results in improving the cognitive ability in a subject suffering from cognitive impairment associated with a tauopathy and reducing tau aggregates and neurofibrillary tangles.

M3 - Patent

M1 - EP4034240

ER -